Mir-16 Decreases the Expression of VTI1B and SMPD1, Genes Involved in Membrane-Protein Trafficking in Melanoma
Open Access
Abstract
Introduction: The interface between T cells and the tumor microenvironment, termed the ‘immunological synapse’, consists of multiple checkpoint protein pairs co-expressed on both sides of the synapse. mir-16, a microRNA from a widely known tumor-suppressor family of miRNAs, was previously shown by us to be downregulated in melanoma. As other miRNAs from this family have been shown to directly target checkpoint proteins, here we investigated whether miR-16 influences the expression patterns of checkpoint proteins in melanoma. Methods: Single-cell gene expression data from the melanoma microenvironment were retrieved from a public database. Melanoma cell lines were established from metastatic lesions and transiently transfected with an hsa-miR-16-5p-mimic RNA or a mir-16-expressing plasmid. The mRNA expression profiles were analyzed using an Affymetrix microarray. Direct targets of miR-16 were identified by luciferase reporter assays. Protein levels were assessed by Western blotting. Results: Bioinformatic analysis revealed that the expression levels of eight checkpoint mRNAs, known to be present on the melanoma side of the immunological synapse, were highly correlated. Four of these mRNAs contained putative binding sites for the miR-15/16 family. miR-16 expression was significantly reduced in melanoma cells, compared to normal melanocytes. Luciferase reporter assays demonstrated that miR-16 directly targets the 3′ untranslated regions (3′UTRs) of CD40, CD80. The mRNAs downregulated following miR-16 overexpression were highly enriched for genes involved in autophagy, vesicle-mediated transport, and the regulation of protein membrane localization. Among these, VTI1B and SMPD1 were confirmed to be direct targets of miR-16. Transient overexpression of miR-16 resulted in a significant reduction in SMPD1 and VTI1B levels in melanoma cell lines. Conclusions: Our findings suggest that miR-16 potentially modulates melanoma tumorigenesis, metastasis and immunogenicity by altering the composition of checkpoint proteins at the immunological synapse and by regulating cellular pathways associated with intracellular trafficking and transmembrane protein presentation.Keywords
Funding Information
- Israeli Scientific Foundation (1914/16, 20171188)
- Israeli Cancer Association (1914/16, 20171188)
- Shamir Medical Center (1914/16, 20171188)
This publication has 37 references indexed in Scilit:
- Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy ImplicationsImmunity, Inflammation and Disease, 2025
- Molecular patterns of resistance to immune checkpoint blockade in melanomaNature Communications, 2024
- Vti Proteins: Beyond Endolysosomal TraffickingNeuroscience, 2019
- miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpointNature Communications, 2016
- Serum miR-16: A Potential Biomarker for Predicting Melanoma PrognosisJournal of Investigative Dermatology, 2016
- microRNAs in Cancer2010
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols, 2008
- Ceramide-enriched membrane domainsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2005
- Antigenicity of human melanoma cells transfected to express the B7-1 co-stimulatory molecule (CD80) varies with the level of B7-1 expressionCancer Immunology, Immunotherapy, 2000
- Expression of the co‐stimulatory molecule CD40 on melanoma cellsInternational Journal of Cancer, 1996